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Neoplastic transformation of 
Human Mesenchymal stromal Cells 
Mediated via LIN28B
Radhakrishnan Vishnubalaji1, Ramesh elango1, Mashael Al-toub2,3, 
Muthurangan Manikandan3, Ammar Al-Rikabi4, Linda Harkness  5,6, Nicholas Ditzel6, 
Muhammad Atteya3,7, Rimi Hamam8, Musaad Alfayez3, Abdullah Aldahmash3,9, 
Moustapha Kassem3,6,10 & Nehad M. Alajez1
Bone marrow stromal (Mesenchymal) stem cells (MsCs) are multipotent bone cells capable of 
differentiating into mesoderm-type cells, such as osteoblasts and adipocytes. Existing evidence 
suggests that transformation of MsCs gives rise to sarcoma. In order to identify the molecular 
mechanism leading to spontaneous transformation of human bone marrow MsCs (hBMsCs), we 
performed comprehensive microRNA (miRNA) and mRNA profiling in the transformed hBMSC-Tum line 
compared to the parental clone. As a result, we identified multiple dysregulated molecular networks 
associated with the hBMsC transformed phenotype. LIN28B was upregulated 177.0-fold in hBMSC-
tum, which was associated with marked reduction in LET-7 expression and upregulated expression 
of its target HMGA2. targeted depletion of LIN28B or exogenous expression of LET-7b suppressed 
hBMSC-Tum proliferation, colony formation, and migration. On the other hand, forced expression of 
LIN28B promoted malignant transformation of parental hBMsC cells as shown by enhanced in vitro 
colony formation, doxorubicin resistance, and in vivo tumor formation in immunocompromised mice. 
Analysis of LIN28B and HMGA2 expression levels in cohorts from The Cancer Genome Atlas sarcoma 
dataset revealed a strong inverse-relationship between elevated expression and overall survival (OS) 
in 260 patients (p = 0.005) and disease-free survival (DFS) in 231 patients (p = 0.02), suggesting LIN28B 
and HMGA2 are important regulators of sarcoma biology. Our results highlight an important role for 
the LIN28B/LET-7 axis in human sarcoma pathogenesis and suggest that the therapeutic targeting of 
LIN28B may be relevant for patients with sarcoma.
Sarcomas are malignant tumors that arise from transformed cells of stromal or mesenchymal origin. Despite their 
rarity, sarcomas represent a clinical challenge requiring a better understanding of their pathogenesis, as well as a 
need for the identification of novel markers to be employed in targeted therapy1.
A number of recent studies have demonstrated that stromal human mesenchymal stem cells (hMSCs) repre-
sent the cells-of-origin of sarcomas. We have previously reported transformed phenotype of immortalized pri-
mary bone marrow-derived human stromal (mesenchymal) cells upon continuous passaging in culture2. Results 
from other studies are consistent with these initial findings that hMSCs were serially transformed by a retrovirus 
containing human telomerase reverse transcriptase, simian virus 40 large T antigen (SV40 TAg), and lentivirus 
containing oncogenic H-Ras, leading to the formation of sarcoma-like tumors in vivo3.
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The transforming property of MSCs and their role as sarcoma-initiating cells suggest their use as a suitable 
model to investigate sarcoma pathogenesis4, and to identify mechanism(s) underlying malignant transformation. 
Herein, we performed global mRNA and microRNA (miRNA) expression profiling in non-transformed parental 
hBMSC and transformed hBMSC-Tum cells. Our data revealed distinct miRNA and mRNA expression profiles 
associated with malignant transformation, highlighted a pivotal role for the LIN28B/LET-7 axis in the transfor-
mation process of hBMSC, and indicated that elevated expression of LIN28B and HMGA2 may be predictive of 
poor clinical outcome in sarcoma patients.
Results
Multiple altered genetic pathways were associated with the transformed phenotype of hBM-
sC-tum cells. Few studies have investigated the epigenetic mechanisms associated with human sarcoma 
pathogenesis5–8. In the current study, we employed a model of human sarcoma generated via the spontaneous trans-
formation of immortalized human bone marrow stromal cells (hBMSC) upon continuous passaging in culture. The 
hBMSC-Tum cells exhibited higher proliferation rates in vitro compared to parental control cells (Fig. 1a, upper 
left panel) and formed sarcoma-like tumors in vivo that were associated with high mitotic activity and increased 
angiogenesis (Fig. 1a, upper right panel). These tumors were positive for vimentin and negative for cytokeratin, 
confirming a mesenchymal origin (Fig. 1a, lower panels). Global gene expression profiling of the hBMSC-Tum 
cells revealed substantial changes in their transcriptome compared to the parental non-transformed hBMSC line 
(Fig. 1b). We identified 3269 genes that were differentially expressed (fold change ≥ 2.0; P (Corr), 0.05), which 
are shown in Supplementary Table 1. We found several of the upregulated genes in our study to be associated 
with different types of human sarcomas, including GPR65, ARHGDIB, PPARG, HSD11B1, KYNU, SPRR2A, CCR1, 
PEG10, CLDN14, TFPI2, CYP2J2, PTPRN2, HLA-DQB1, CCL3, MAGEA8, COL5A3, HLA-DPA1, GFPT2, AIM2, 
HLA-DPB1, and TNNT19,10. Based on gene expression, the highest resemblance of hBMSC-Tum was with lipo-
sarcoma (7.5%), rhabdomyosarcoma (7.0%), malignant fibrous histiocytoma (6.3%), and fibrosarcoma (5.2%) 
(Supplementary Fig. 1). The distribution of the top-15 enriched pathways for the differentially-expressed genes in 
the hBMSC-Tum cells is shown in Fig. 1c and Supplementary Table 2. Several of the identified genetic pathways 
play important roles in stromal (mesenchymal) stem cell differentiation, such as ossification and adipogenesis, 
highlighting the maintenance of the stromal phenotype during transformation. We also observed the presence 
of an inflammatory signature in the hBMSC-Tum cells. The expression of a selected number of genes (ACTB, 
LIN28B, HMGA2, IGF2BP2, and SLIT3) was validated using qRT-PCR, demonstrating good concordance with the 
microarray data (Fig. 1d, upper panel). LIN28B was among the highly expressed genes based on the microarray data 
(approximately a 177.0 fold-change) and western blot analysis corroborated its upregulation in the hBMSCs-Tum 
cells (Fig. 1d, lower panel). We also noted the downregulation of CD24 and the upregulation of HLA-DR in the 
hBMSC-Tum cells, which was further validated by results from flow cytometry analysis (Fig. 1e). The expression of 
other hBMSC surface markers did not change significantly during transformation (Supplementary Fig. 2).
Expression profiling of miRNA in hBMSC-Tum cells. To gain more insight into the epigenetic mech-
anisms leading to transformation of hBMSC-Tum cells, we performed global miRNA expression profiling of the 
hBMSC-Tum cells compared to non-transformed hBMSC cells. Cluster analysis revealed a distinct separation of 
the two cell lines based on their miRNA expression signatures (Fig. 2a). The list of differentially expressed miR-
NAs in the hBMSC-Tum cells compared to parental hBMSC cells is shown in Supplementary Table 3. The expres-
sion of a selected panel of miRNAs (Let-7b, Let-7g, Let-7i, miR-98, and miR-218) was subsequently validated 
using a Taqman microRNA assay and demonstrated good concordance with the microarray data (Fig. 2b). In 
silico prediction revealed approximately 22% of the upregulated genes to be potential targets of the downregulated 
miRNAs in the hBMSC-Tum cells (Fig. 2c). Similarly, approximately 10% of the downregulated genes were found 
to be potential targets of the upregulated miRNAs in the hBMSC-Tum cells (Fig. 2d). Common upregulated and 
downregulated genes from Fig. 2c,d were subsequently subjected to ingenuity pathway analysis (IPA), which 
provides a powerful tool to predict the increase or decrease in downstream biological activities and functions, 
which hare are likely to be casually affected by the transcriptome data. Figure 2e presents a high-level tree map of 
affected downstream functional categories based on common up and downregulated genes in hBMSC-Tum and 
predicted targets of differentially expressed miRNAs. This analysis revealed remarkable enrichment in several 
functional categories, mainly those involved in cancer cell growth, and proliferation and invasion (Fig. 2F,g). 
Additionally, genes associated with increased cell viability and survival were enriched, while genes associated 
with cell death were diminished (Fig. 2h). Top 5 enriched and top 5 diminished functional categories are shown in 
Fig. 2i. Growth and proliferation of cancer cells network is depicted in Fig. 2j, which highlighted a role for Lin28B 
and HMGA2 in this network. Upstream regulator analysis revealed significant enrichment in several mechanistic 
networks including SMARCA4, TNF, FOXO1, NFkB (complex), CAMP, Mek, CG, PPRC1, TGFB1, ERK, IL1B, 
PGR, and P38 MAPK (Supplementary Table 4).Taken together, our data revealed a significant increase in tumour 
growth, proliferation, and invasion, while functional categories associated with cell death were suppressed.
LIN28B/LET-7 axis is associated with the transformed phenotype of hBMSC-Tum cells. Global 
mRNA and miRNA expression data revealed the upregulation of LIN28B and the downregulation of several mem-
bers of the LET-7 family in the hBMSC-Tum cells. LIN28B is known to inhibit processing and maturation of 
the LET-7 family miRNAs, while mature LET-7 is also known to target LIN28B11. To investigate this plausible 
molecular mechanisms, we overexpressed LET-7b in hBMSC-Tum cells, which led to significant changes in their 
global gene-expression profile (Fig. 3a,b). Among the highly downregulated genes, HMGA2, LIN28B, CCL3, and 
DICER1 were selected and validated using qRT-PCR (Fig. 3c). Downregulation of LIN28B in the hBMSC-Tum 
cells in response to LET-7b overexpression was also validated using western blot analysis (Fig. 3d). In order 
to identify the set of genes regulated by the LIN28B/LET-7 axis in in this system, we assessed the intersection 
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Figure 1. The tumorigenic cell line (hBMSC-Tum) exhibited changes in multiple genetic pathways. The 
tumorigenic stromal human mesenchymal cell line (hBMSC-Tum) was compared to the non-tumorigenic 
hBMSC cell line in vitro and in vivo. (a) Cell viability determined using an alamarBlue assay (upper left 
panel). Data are presented as the mean fold change ± S.E., n = 48 wells per condition from two independent 
experiments. ***P < 0.0005. Representative hematoxylin and eosin (H & E) staining for histological 
examination (upper right panel) showing a sarcoma-like phenotype for the hBMSC-Tum xenograft, the 
presence of multiple mitotic cells (yellow arrow), and vascularization (black arrow). The tumors were positive 
for vimentin (lower left) and were negative for cytokeratin (lower right). (b) Hierarchical clustering of hBMSC-
Tum cells compared to parental hBMSC cells based on differentially expressed mRNA levels as determined 
by microarray analysis. Each column represents one technical replica and each row represents an mRNA 
transcript. The expression level of each gene in a single sample is depicted according to the color scale. (c) Pie 
chart illustrating the distribution of the top-15 genetic pathways based on differentially expressed genes in the 
hBMSC-Tum cells compared to that in the parental hBMSC cells. The size of the chart segment corresponds 
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between genes that were upregulated in the hBMSC-Tum cells and the genes downregulated in hBMSC-Tum cells 
transfected with LET-7b, and compared the results with the list of in silico-predicted LET-7b-target genes (Fig. 3e). 
This analysis revealed 34 genes that were common to all three conditions (Fig. 3e). HMGA2, LIN28B, and several 
members of the insulin-like growth factor-binding protein family were among the genes identified (Fig. 3f).
the LET-7 family directly targeted LIN28B and HMGA2 in hBMSC-Tum cells. We subsequently 
focused on LIN28B and HMGA2 for further investigation given their documented roles in several human can-
cers12. Forty-six miRNAs downregulated in the hBMSC-Tum cells were also predicted by the in silico analysis 
to target LIN28B and HMGA2 (Fig. 4a). Five of those miRNAs belonged to the LET-7 family (Fig. 4b). Over 
expression of LET-7b (as a representative of the LET-7 family), as well as siRNA-mediated knockdown of 
LIN28B, reduced colony formation (Fig. 4c) and proliferation (Fig. 4d) of the hBMSC-Tum cells. In addition, 
over-expression of LET-7b or siRNA-mediated knockdown of LIN28B expression led to significant inhibition of 
real-time migration of the hBMSC-Tum cells (Fig. 4e).
Forced expression of LIN28B led to transformation of the parental hBMSC cells. Our data 
highlighted a role for the LIN28B/LET-7 circuit in hBMSC-Tum cells. Therefore, we sought to determine if 
LIN28B could transform the parental hBMSC cells. Parental non-tumorigenic hBMSC line were transduced 
using lentiviral vector carrying human LIN28B and the global mRNA gene expression in the transduced cells 
was determined using microarray analysis. Hierarchical clustering comparing the hBMSC-LIN28B cells to the 
hBMSC-mCherry-control cells revealed a clear separation of the two cell lines (Fig. 5a). The top-15 enriched 
genetic pathways, based on the upregulated genes in the hBMSC-LIN28B cells, is shown in Fig. 5b and included 
those involved in focal adhesion, integrin cell surface interaction, G protein coupled receptors, and others. The 
expression levels of a number of these genes related to the LIN28B/LET-7 axis (LIN28B, HMGA2 and DICER1) 
were subsequently selected and validated using qRT-PCR (Fig. 5c). Expression of the LIN28B protein in the 
hBMSC-LIN28B cells was validated by western blot analysis, as shown in Fig. 5c. Forced expression of LIN28B 
enhanced the clonogenic potential of hBMSC cells (Fig. 5d). Furthermore, for in vivo assessment of tumorigenic 
potential, hBMSC-LIN28B cells were subcutaneously implanted into immune deficient SCID mice and tumor 
formation was monitored. Data presented in Fig. 5e demonstrates the progressive tumor growth of the implanted 
hBMSC-LIN28B cells, whereas the control cells did not form tumors. Histological examination of the tumors 
revealed proliferating fibromyxoid sarcoma with increased mitotic figures and angiogenesis (Fig. 5f).
Differential sensitivity of hBMSC-Tum, hBMSC-LIN28B, and parental hBMSC cell lines to dox-
orubicin treatment. Doxorubicin is an important chemotherapeutic agent in the treatment of sarcoma but 
a significant number of aggressive sarcomas exhibit doxorubicin resistance13. A number of studies has implicated 
the let-7 family in mediating chemotherapy resistance in other cancer types14,15. Therefore, we tested a possible 
role for LIN28B in doxorubicin resistance in sarcoma. We compared the chemo-sensitivity of hBMSC-LIN28B 
cells to doxorubicin to the sensitivity of hBMSC-Tum cells. Both types of cells were incubated in the presence 
of doxorubicin (7.8 nM to 125 nM) for 5 days and the apoptotic/necrotic responses were assessed. Doxorubicin 
concentrations >31.2 nM were toxic to all cells (Fig. 6). At 15.6 nM, hBMSC control cells exhibited formation of 
perinuclear cytoplasmic vacuoles. Compared to doxorubicin treatment at 31.2 nM, the number of cells containing 
apoptotic bodies (condensed chromatin and nuclear fragmentations) and dead cells was increased by treatment of 
the cells with 62.5 nM and 125 nM doxorubicin. However, these morphological changes were only observed in the 
hBMSC-Tum cells at the higher concentrations (Fig. 6, second panel). The hBMSC-LIN28B cells exhibited greater 
doxorubicin resistance compared to all the other cells types (Fig. 6, fourth panel). Similar differential sensitivity 
was also observed using flow cytometry cell cycle analysis (Supplementary Fig. 3).
LIN28B expression was a possible prognostic marker for sarcoma. To corroborate the clinical rele-
vance of our findings, we examined the expression of LIN28B and HMGA2 in sarcoma cohort using the StarBase 
database. Data presented in Fig. 7a revealed strong correlation between Lin28B and HMGA2 expression in 263 
sarcoma patients (r = 0.36, p = 1.1 × 10−9). Additionally, inverse correlation between lET-7b and LIN28B was 
observed in the same cohort (r = −0.3, p = 4.1 × 10−7, Fig. 7b). Overall survival (OS, n = 260) and disease free 
survive l (DFS, n = 231) analysis on the TCGA sarcoma dataset revealed strong associations between the elevated 
expression levels of these proteins and poor OS (p = 0.005, Fig. 7c) and poor DFS (p = 0.02, Fig. 7d), thus impli-
cating LIN28B and HMGA2 as clinically relevant biomarkers for sarcoma.
Discussion
The notion that hMSCs being representative of the cell-of-origin of sarcomas has been considered in a number of 
recent studies; however, the molecular mechanisms leading to malignant transformation are still unknown. In the 
current study, we identified miRNA and mRNA expression signatures that were associated with the hBMSC trans-
formed phenotype. In addition, we identified LIN28B/LET-7 as a possible molecular circuit underlying the trans-
formed phenotype of hBMSC in vitro and associated it with the poor clinical prognosis for patients with sarcoma.
to the fold-enrichment. (d) The expression levels of genes selected from the microarray data validated using 
qRT-PCR (upper panel). Data are presented as the mean ± S.E., n = 6 technical replicas. ***P < 0.0005. 
Representative immunoblotting results showing the upregulation in the expression of the LIN28B protein in 
hBMSC-Tum cells compared to its expression levels in the control cells (lower panel). Quantification of relative 
protein expression is shown form 3 technical replicas. (e) Cell surface antigen expression on hBMSC and 
hBMSC-Tum cells as shown by FACS analysis.
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Figure 2. The expression profile of miRNA in the tumorigenic hBMSC-Tum cell line. (a) Hierarchical 
clustering of hBMSC-Tum cells compared to parental hBMSC cells based on miRNA expression levels. Each 
column represents a technical replica and each row represents an mRNA transcript. The expression level of 
each miRNA in a single sample is depicted according to the color scale. (b) Validation of the expression levels 
of miRNAs selected from the microarray data (RNU44, LET-7b, LET-7g, LET-7i, miR-98, and miR-218) using 
Taqman qRT-PCR. Data are presented as the mean ± S.E., n = 6 technical replicas. ***P < 0.0005. (c) Venn 
diagram depicting the overlap between the predicted gene targets for the downregulated miRNAs (based 
on TargetScan) versus the differentially upregulated genes in hBMSC-Tum cells compared to that in non-
tumorigenic parental hBMSC cells. (d) Venn diagram depicting the overlap between the predicted gene targets 
for the upregulated miRNAs (based on TargetScan) versus the differentially downregulated genes in hBMSC-
Tum cells compared to that in parental hBMSC cells. (e) Tree map (hierarchical heat map) depicting affected 
functional categories based on common genes from 2c and 2d where the major boxes represent a category of 
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A number of previous models have been employed in vitro to study sarcoma biology, including transformed 
hMSCs using specific genetic elements4. In contrast to these studies, our study employed a biologically rele-
vant model of spontaneously transformed hBMSCs and were able to compare non-transformed and transformed 
cells with the same genetic background. In addition, in contrast to the other models, the hBMSC-Tum model 
employed in current study maintained a normal karyotype16, helping to increase the sensitivity in identifying rel-
evant molecular pathways associated with transformation. Finally, the relevance of this model was demonstrated 
by it exhibiting a similar molecular signature to those reported for clinically retrieved sarcomas9. Furthermore, 
our data revealed substantial similarities between the miRNA expression profile of transformed hBMSCs and 
those reported for human sarcomas. Approximately 30% of the altered miRNAs in human sarcomas reported 
by Subramanian et al.8 were also altered in transformed hBMSC-Tum cells identified in our current study and 
included hsa-miR-214, hsa-miR-379, hsa-miR-376a, hsa-miR-335, hsa-miR-10a, hsa-miR-29b, hsa-miR-29c, 
hsa-miR-30d, hsa-miR-143, hsa-miR-145, hsa-miR-195, hsa-miR-10b, hsa-let-7b, hsa-let-7d, hsa-miR-26a, 
hsa-miR-26b, hsa-miR-16, hsa-miR-15a, hsa-miR-497, hsa-miR-222, hsa-miR-424, hsa-miR-21, hsa-miR-218, 
and hsa-miR-30c.
Cumulative evidence implicates miRNAs and their regulatory networks in arbitrating tumor progression, 
mainly through the regulation of their relevant mRNA targets17. LIN28A and LIN28B selectively inhibit LET-7 
miRNA expression and biogenesis in embryonic stem cells (ESCs), and block the expression of LET-7 through 
TUTase-dependent and independent mechanisms18,19. In addition, compelling evidence supports the role for 
LIN28 as an oncogene, including its direct targeting by the LET-7 family and its effect in combination with several 
known oncogenes on cell reprogramming11,20,21. In addition, LIN28A and LIN28B are upregulated in several 
advanced human cancers and are reliable predictors of a poor prognosis12,21. However, the role of the LIN28/
LET-7 axis in hBMSC transformation and sarcoma pathogenesis remains unknown.
We observed the upregulation of LIN28B and downregulation of the LET-7 family in the tumorigenic trans-
formation of hBMSCs. The tumor-suppressive LET-7 miRNA family targets oncogenes such as HMGA2, LIN28B, 
and IGF2BP1 to form a LET-7 antagonizing, self-promoting, oncogenic triangle22. Concordantly, our data 
demonstrated that HMGA2 and LIN28B were upregulated in hBMSC-Tum cells and were suppressed upon the 
re-expression of LET-7. Iliopoulos et al. reported that the activation of NFKB by Src induces cellular transforma-
tion via the LIN28B, LET-7, and IL-6 circuit23. The hBMSC-Tum model exhibited high levels of pro-inflammatory 
markers such as IL1β and IL6. Therefore, it is plausible that high levels of inflammation during the transforma-
tion of parental hBMSC cells induces the expression of LIN28B, followed by the downregulation of LET-7 and 
increased expression levels of IL6, which ultimately results in a transformed phenotype. Thus, we propose a 
model for the role for the LIN28B/LET-7 axis in the underlying mechanism of hBMSC transformation (Fig. 7e). 
Concordant with our findings, interrogation of LIN28B expression in the Cancer Cell Line Encyclopedia (CCLE) 
database revealed upregulated expression of LIN28B in a number of Ewing’s sarcoma cell lines (Supplementary 
Figure 4). While our proposed model highlights a role for LIN28B in cellular transformation via LET-7, it is plau-
sible that LIN28B may also promote cellular transformation through a LET-7 independent mechanism24.
Our data highlighted a role for LIN28B in conferring doxorubicin resistance in vitro. Edmonson et al. reported 
a lower efficacy of doxorubicin when it is administered alone compared to when it is combined with ifosfamide or 
with mitomycin and cisplatin, suggesting the presence of a resistance mechanism in patients with advanced soft 
tissue sarcomas13. Therefore, it is possible that elevated levels of LIN28B indeed mediate doxorubicin resistance 
in those patients. In agreement with those findings, patient survival data positively correlated elevated levels of 
LIN28B and HMGA2 with poor clinical outcome in sarcoma patients. Our data support the clinical relevance of 
LIN28B and HMGA2 as possible prognostic markers and as molecular targets for novel therapeutic approaches 
in sarcoma.
Materials and Methods
ethics statement. All animal procedures were approved by the local ethical committees on animal exper-
iments at the University of Southern Denmark. All methods were performed in accordance with the relevant 
guidelines and regulations of the animal care committee at the University of Southern Denmark.
Cell lines and culture. We used a well-characterized hTERT-immortalized adult hBMSC cell line that 
expressed all the known markers of primary hBMSCs and is able to form bone and establish the bone mar-
row microenvironment following in vivo implantation at early population doublings2,25,26. For simplicity, will 
refer to this model as hBMSC for the remained of this manuscript. We also used its transformed counterpart 
(hBMSC-Tum), which spontaneously arose during long-term culturing27. Both cell lines were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 4500 mg/l d-glucose, 4 mM l-glutamine, 
110 mg/l sodium pyruvate, 10% fetal bovine serum (FBS), 1% penicillin–streptomycin, and nonessential amino 
acids as previously described2.
Lentiviral transduction and pre-miR transfection. Transduction was performed in accord-
ance with our previously published protocols28. Briefly, lentiviral particles encoding for human LIN28B 
(LP-OL05603-LX304-0200-S) or control lentiviral particles mCherry (LP-MCHR-LV105-0205) were purchased 
diseases and functions. (f) Cellular growth and proliferation, (g) cellular movements, and (h) represent cell 
death and survival functional category. Each individual colored rectangle is a particular biological function 
or disease and the color range indicates its predicted activation state: increasing (orange), or decreasing 
(blue). Darker colors indicate higher Z-scores. (i) Bargraph depicting top 5 activated and bottom 5 suppressed 
functional categories. X axis present the activation Z score. (j) Depicts the proliferation of cancer cells network.
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Figure 3. Changes in LET-7 expression regulates the transformed phenotype of the hBMSC-Tum cell line.  
(a) Measurement of the expression level by qRT-PCR of LET-7b in hBMSC-Tum cells transfected with pre-miR 
hsa-Let-7b. (b) Hierarchical clustering of hBMSC-Tum-Let-7b compared to that of hBMSC-Tum-control cells 
based on differentially expressed mRNA levels according to microarray analysis. Each column represents one 
technical replica and each row represents an mRNA transcript. The expression level of each gene in a single sample 
is depicted according to the color scale. (c) Validation of the expression levels of genes selected from the microarray 
data (HMGA2, LIN28B, CCL3 and DICER1) using qRT-PCR. Data are presented as the mean ± S.E., n = 6 technical 
replicas. ***P < 0.0005. (d) Western blot analysis showing the downregulation of LIN28B protein expression in 
hBMSC-Tum-Let-7b cells compared to that in the control cells. Quantification of relative protein expression is shown 
form 3 technical replicas (e) Venn diagram depicting the overlap between the predicted gene targets for the LET-7 
family (based on TargetScan algorithm) compared to downregulated genes in hBMSC-Tum-LET-7b cells and the 
differentially upregulated genes in hBMSC-Tum cells. (f) List of 34 common genes from panel 3e.
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from Genecopoeia Inc. (Rockville, MD, USA). The hBMSC cells (1.5 × 105) were seeded into 24-well plates 
with complete DMEM. Twenty-four hours later, after the cells had obtained approximately 80% confluency, the 
medium was removed and 20 μl of crude lentiviral particles in 500 μl of DMEM + 5% heat-inactivated serum 
(Invitrogen) and 1% Pen–Strep supplemented with polybrene (8 μg/ml; Sigma, St. Louis, MO, USA) were added 
to the cells. Seventy-two hours later, the medium was removed and transduced cells were selected with puromycin 
(1 μg/ml; Sigma, St. Louis, MO, USA) for 1 week or until stably transduced cells were generated.
The pre-miR-negative control, pre-miR hsa-let-7b-5p, scrambled siRNA control, and siRNA targeting human 
LIN28B were purchased from Applied Biosystems (Invitrogen, Carlsbad, CA, USA). Transfection was per-
formed using a reverse transfection approach as previously described17. Briefly, pre-miRs or siRNA at a final 
concentration of 30 nM was diluted in 50 μl of Opti-MEM (11058-021; Gibco, Carlsbad, CA, USA), and 1 μl of 
Figure 4. Changes in the LIN28B/LET-7 axis regulated the transformed phenotype of the hBMSC-Tum cell 
line. (a) Venn diagram depicting the overlap between miRNAs targeting LIN28B and HMGA2 (in silico), 
which were downregulated in the hBMSC-Tum cells. (b) Illustration depicting the regulation of LIN28B and 
HMGA2 by the LET-7 family, which are downregulated in the hBMSC-Tum cell line according to the current 
literature. Over expression of LET-7b or knockdown of LIN28B in the hBMSC-Tum cell line reduced the colony 
formation potential (c). For CFU assay, the initial seeding density was 1.5 × 104 cells in the first well, followed 
by serial 2-fold dilution. (d) Cell viability was reduced as well. Data are presented as the mean ± S.E., n = 6, 
***P < 0.0005. (e) Real time migration of different treatment groups toward 1% and 10% FBS-containing media 
using the RTCA system. Data are represented as mean ± S.D. from 3 technical replicas.
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Figure 5. The parental hBMSC cell line overexpressing LIN28B (hBMSC-LIN28B) exhibited a transformed 
phenotype. (a) Hierarchical clustering of hBMSC-LIN28B compared to the control hBMSC-mCherry cells based on 
differentially expressed mRNA levels determined by microarray analysis. Each column represents one replica and 
each row represents an mRNA transcript. Expression level of each gene in a single sample is depicted according to the 
color scale. (b) Pie chart illustrating the distribution of the top-15 genetic pathways enriched in the hBMSC-LIN28B 
cells compared to that in the control hBMSC cells based on differentially expressed genes. The size of the chart wedge 
corresponds to fold-enrichment. (c) Expression levels of genes selected from the microarray data that were validated 
using qRT-PCR and western blot analysis. Quantification of relative protein expression is shown form 3 technical 
replicas. The hBMSC-LIN28B cell line exhibited enhanced in vitro colony formation (d). For CFU assay, the initial 
seeding density was 1.5 × 104 cells in the first well, followed by serial 2-fold dilution. (e) The hBMSC-LIN28B cell 
line demonstrated tumor development in immunocompromised mice. Mice were implanted subcutaneously with 
hBMSC-LIN28B cells (mixed with matrigel) and on day 33, tumors were excised and weights were measured. Data 
on the y-axis are presented as tumor growth rate (mg/day) using the formula (tumor growth rate = weight (mg)/no. 
of days). (f) Histological analysis revealed sarcoma-like phenotype with the presence of many mitotic figures (yellow 
arrow) and angiogenesis (black arrow). Hematoxylin and eosin staining, 40×.
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Lipofectamine 2000 (catalogue No. 52758; Invitrogen) was diluted in 50 μl OPTI-MEM. The diluted pre-miR, 
siRNA, and Lipofectamine 2000 were mixed and incubated at ambient temperature for 20 min. Twenty microlit-
ers of transfection mixture was added to the tissue culture plate and subsequently 10,000 cells in 60 μl transfection 
medium (complete DMEM without antibiotics) were added to each well. Twenty-four hours later, the transfection 
cocktail was replaced with complete DMEM.
Gene and miRNA expression profiling. RNA isolation, and the expression profiling of genes and miRNA were 
performed according to our previously published protocols17,28,29. In brief, total RNA was isolated using a Total Tissue 
RNA Purification Kit from Norgen-Biotek Corp. (Thorold, ON, Canada) and was quantified using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Total RNA was labeled and then hybridized with an 
Agilent Human SurePrint G3 Human GE 8 × 60 k or Human 8 × 60 k miRNA microarray chip (Agilent Technologies, 
Palo Alto, CA, USA). All microarray experiments were conducted at the Microarray Core Facility in the Stem Cell Unit, 
Department of Anatomy, King Saud University College of Medicine. Data were subsequently normalized and analyzed 
using GeneSpring 13.0 software (Agilent Technologies). Pathway analyses were conducted using the Single Experiment 
Pathway analysis feature in GeneSpring 13.0. A twofold cut-off with P < 0.05 was used. Target prediction was conducted 
using the TargetScan database and the built-in feature of GeneSpring 13.0.
Gene set enrichment and modeling of gene interactions networks. Up and downregulated genes 
which are predicted targets of differentially expressed miRNAs in the hBMSC-Tum line were imported into the 
Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems; www.ingenuity.com/) and were subjected to 
functional annotations and regulatory network analysis using upstream regulator analysis (URA), downstream 
effects analysis (DEA), mechanistic networks (MN) and causal network analysis (CNA) prediction algorithms. 
The p value is the negative log of P and represents the possibility that focus genes in the network being found 
together by chance. Z score corresponds to the enrichment of particular functional category30,31.
mRNA and miRNA validation by qRt-pCR. Expression levels of the mRNAs were validated using 
SYBR Green-based quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) with an Applied 
Biosystems ViiA™ 7 Real-Time PCR System as previously described17. The total RNA (500 ng) was reverse 
Figure 6. Differential sensitivity of cell lines hBMSC-Tum, hBMSC-LIN28B, and control hBMSC to 
doxorubicin treatment. Drug sensitivity of hBMSC-Tum and hBMSC-LIN28B cells and their respective control 
cells hBMSC and hBMSC-mCherry was assessed by doxorubicin treatment at concentrations ranging from 
7.9 nM to 125 nM. Cells were stained with acridine orange and ethidium bromide in order to detect apoptotic 
cells (green) with condensed chromatin and apoptotic bodies, and dead cells (red). The arrow indicates the 
perinuclear cytoplasmic vacuoles, the square indicates apoptotic bodies, and the circle indicates dead cells 
(Scale bar = 200 µm). Data are representative of two replicas for each experimental condition, where more than 
6 images were captured per condition. Quantification data from four representative images is presented as the 
mean ± S.E., n = 4. ***P < 0.0005.
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transcribed into complementary DNA (cDNA) using a High Capacity cDNA Reverse Transcript Kit (catalogue 
No. 4368814; ABI) according to the manufacturer’s protocol. Relative levels of mRNA were determined using 
the cDNA as template in real-time PCR analysis using the Applied Biosystems ViiA 7 System. Primer sequences 
Figure 7. Expression of LIN28B and HMGA2 in sarcoma tissues were associated with a poor prognosis in 
patients. (a) Correlation between Lin28B and HMGA2 expression in a cohort of 263 sarcoma patients based on 
the starbase database. (b) Correlation between let-7b and Lin28B expression in 261 sarcoma patients based on 
the starbase database. Kaplan-Meier curves illustrate the duration of overall survival (OS) of 260 patients (c) and 
disease-free survival (DFS) of 231 patients (d) according to the expression of LIN28B and HMGA2 in cohorts 
of patients in The Cancer Genome Atlas (TCGA) sarcoma dataset. Based on the log-rank analysis, expression of 
LIN28B and HMGA2 were associated with poor OS (P = 0.005) and poor DFS (P = 0.02). (e) A proposed model 
for the role of the LIN28B/LET-7 axis in hBMSC transformation into sarcoma.
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used in the current study are listed in Table 1. The relative expression levels were calculated using the −ΔΔCT 
method. The housekeeping gene for β-actin was used as an endogenous control. For miRNA validation, 10 ng of 
total RNA was reverse transcribed using a TaqMan MicroRNA Reverse Transcription Kit (catalogue No. 4366596; 
ABI) and the relative miRNA expression levels were determined using TaqMan Universal Master Mix II, no UNG 
(catalogue No. 4440040; ABI). The relative expression levels were calculated using the −ΔΔCT method. RNU44 
was used as an endogenous control.
Immunophenotyping by flow cytometry (FACS). Immunophenotypic analysis was performed in 
accordance with our previously published protocols32. In brief, cells were harvested and washed twice in ice-cold 
phosphate buffered saline (PBS) supplemented with 0.5% bovine serum albumin and resuspended at 106 cells/
ml. Then, 10 μl of mouse anti-human CD24-FITC and HLADR-PE conjugated antibodies (from BD Biosciences, 
San Jose, CA, USA) was added to 100 μl of cell suspension. Cells were incubated for 30 min at 4 °C in the dark, 
washed with PBS, resuspended in 500 μl of PBS, and analyzed using a Navios flow cytometer (Beckman Coulter, 
Brea, CA, USA). Living cells were gated in a dot plot of forward vs. side scatter signals obtained on linear scale 
after being analyzed with appropriate negative control using FITC and PE-conjugated mouse IgG1 isotype control 
for nonspecific background. Minimum 5000-gated events were acquired on a log fluorescence scale. Data were 
further analyzed using Kaluza software (1.2 version, Beckman Coulter). For cell cycle analysis, cell pellets were 
collected and washed with phosphate-buffered saline (PBS), and then were resuspended in 1 ml of FACS buffer 
(PBS/0.5% BSA), and then 3 ml of ice-cold 70% ethanol was added to fix the cells for 1 h on ice. Cell pellets were 
subsequently centrifuged, and re-suspended in 500 μL of PBS supplemented with 40 µg/mL RNAse A (Sigma) 
and 50 µg/mL propidium iodine (PI), before being analyzed using a Navious flow cytometer (Beckman Coulter, 
Miami, FL, USA). Staining was detected in the green fluorescence channel (FL1) and the data were analyzed by 
Kaluza software (Beckman Coulter).
Cell migration. Real-time measurement of cell migration was performed using the xCELLigence RTCA DP 
system (ACEA Biosciences, San Diego, CA) as described previously28. Briefly, cells were starved for 24 h in media 
containing 1% serum, followed by seeding 8.0 × 104 cells per well in 16-well microelectronic sensor plates with 
two-chamber trans-well inserts (CIM-plate insert; ACEA Bioscience) containing the appropriate serum con-
ditions. Medium containing 10% serum (chemo-attractant) or 1% serum (control) was added to the bottom 
chambers of the wells.
Measurement of cell viability and colony formation. Viability of the negative control cells compared 
to the pre-miR Let-7b or si-LIN28B cells (hBMSC-Tum) was determined using an alamarBlue assay as previously 
described28. All assays were carried out with the appropriate controls. Briefly, 1 × 104 cells were cultured in 96-well 
plates and the cell viability measured at the indicated time points by adding 10% volume alamarBlue assay reagent 
and measuring the fluorescence at excitation and emission wavelengths of 530 nm and 590 nm, respectively.
The colony forming ability of the control cells compared to the pre-miR Let-7b or si-LIN28B cells 
(hBMSC-Tum), hBMSC-LIN28B cells, and hBMSC-mCherry cells was determined using a clonogenic assay as 
previously described29. Briefly, cells were seeded into 12-well plates at different concentrations of serial diluted 
cells (1:2 to 1:64), with an initial seeding density of 1.5 × 104 cells per well and incubated at 37 °C under 5% 
CO2 for 10 d. The plates were then washed and stained using a Diff-Quik staining set (Siemens Healthcare 
Diagnostics). The plates were scanned and the number of colonies was evaluated under light microscopy.
Western blot analysis. Cells were lysed using RIPA buffer (Pierce Inc, Thermo Scientific, USA) containing 
1 × Halt Protease Inhibitor Cocktail (Pierce Inc., Thermo Scientific). Samples containing 30 µg of total protein 
were electrophoretically separated and blotted using the Bio-Rad V3 Western Workflow system according to 
the manufacturer’s recommendation. Immunoblotting was performed using anti-LIN28B rabbit monoclonal 
No Name Sequence
1 ACTB
F 5′TCAAGATCATTGCTCCTCCTGAG
R 5′ACATCTGCTGGAAGGTGGACA
2 LIN28B
F 5′ GGCCTTGAGTCAATACGGGT
R 5′ GGCACTTCTTTGGCTGAGGA
3 HMGA2
F 5′CAGACCTAGGAAATGGCCACAACAA
R 5′AAATCGAACGTTGGCGCCCC
4 IGF2BP2
F 5′CTGGCCGTGTTCCGGGAGAA
R 5′TTCCTGTTGGCAGGGAGTCCTGG
5 SLIT3
F 5′CCGCCTAACTACACAGGTGAGCTAT
R 5′CGCTGTAGCCAGGGACACACT
6 CCL3
F 5′AAGGACACGGGCAGCAGACA
R 5′AGCAGCAAGTGATGCAGAGAACTGG
7 DICER1
F 5′ATGACCCCTGCTTCCTCAC
R 5′TCTTCCCTGAGCCAGTGTTT
Table 1. List of SYBR green primers used in current study.
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antibody (Ab191881, 1:2000; Abcam, Cambridge, MA). The primary antibody was incubated overnight at 
4 °C. Horseradish peroxidase (HRP)-conjugated goat anti-rabbit was used as the secondary antibody, whereas 
HRP-conjugated anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) antibody (1:1000; Invitrogen) was 
used as a loading control. Chemiluminescent detection was performed using WesternSure Chemiluminescent 
Substrate (LI-COR, Lincoln, NE, USA). Band intensities were quantified using the band quantification tool in 
Image Laboratory 5.0 software (Bio-Rad Laboratories).
Measurement of apoptosis and cell death. Fluorescence-based analysis of apoptosis and the evaluation 
of dead cells were performed after exposure of the cells to different concentrations of doxorubicin (7.8 nM to 
125 nM), using an acridine orange and ethidium bromide (AO/EB) staining method as previously described32. 
Briefly, after treatment, the two groups of cells, hBMSC control vs. hBMSC-Tum and hBMSC-mCherry control 
vs. hBMSC-LIN28B cells were stained with dual fluorescent staining solution (1 µl) containing 100 µg/ml AO and 
100 µg/ml EB (AO/EB, Sigma, St. Louis, MO). Cells were washed twice with PBS and gently mixed with AO/EB 
dye solution (1:100) for 1 min. After staining, the cells were evaluated and photographed using a Nikon Eclipse 
Ti fluorescence microscope and quantified. Cells cultured without drug were considered experimental controls. 
AO/EB staining uses the combination of two dyes to visualize cells with aberrant chromatin organization, apop-
totic bodies, cytoplasmic changes, and dead cells. The differential uptake of AO/EB allows for the identification 
of viable and non-viable cells.
In vivo tumorigenicity assays in immune deficient sCID mice. In vivo tumor formation was 
performed as previously described27. Briefly, six- to eight-week-old female immunodeficient mice (NOD.
CB17-Prkdcscid/J) were utilized in the xenograft experiments. Ten million hBMSC-mCherry or hBMSC-LIN28B 
cells were mixed 1:1 with Matrigel (BD Biosciences, San Jose, CA, USA) and subcutaneously injected into the 
right flank of SCID mice. Tumor mass was assessed on day 33 post implantation. At the end of the experiment, 
tumors were excised, fixed in 10% buffered formalin, embedded in paraffin, and sectioned on a microtome. 
Sections were then stained with hematoxylin and eosin.
Expression and survival analyses of The Cancer Genome Atlas sarcoma dataset. Correlation 
between the expression of LIN28B, HMGA2, and LET-7b in sarcoma patients was assessed using the starBase 
Pan-Cancer database33. Kaplan-Meier curve analysis for the expression of LIN28B and HMGA2 in The Cancer 
Genome Atlas (TCGA) sarcoma dataset, which included 260 patients for overall survival (OS) and 231 patients 
for disease-free survival (DFS), was conducted as previously described32. The log-rank test was used to determine 
statistical significance in the curve comparison analysis.
statistical analysis. Statistical analyses and graph generation were performed using Microsoft Excel 2010 
and GraphPad Prism 6.0 software (GraphPad, San Diego, CA, USA). P-values were calculated using the two-tailed 
t test. P value < 0.05 was considered significant.
Data Availability
Processed data are provided as supplementary datasets.
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